pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT
Cogent Biosciences
Cogent Biosciences clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
- Founded
- 2014
- Employees
- 283
- Programs
- 13
- Drugs
- 8
- Patents
- 10
Cogent Biosciences projects
13 ClinicalTrials.gov programs sponsored by Cogent Biosciences.
Cogent Biosciences has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CGT9486 plus sunitinib
Cogent Biosciences
Advanced Gastrointestinal Stromal Tumors
1 trial -
Bezuclastinib Tablets (Formulation A)
Cogent Biosciences
SSM
1 trial -
Bezuclastinib in combination with sunitinib
Cogent Biosciences
Gastrointestinal Stromal Tumors
1 trial -
CGT4859
Cogent Biosciences
Intrahepatic Cholangiocarcinoma (Icc)
1 trial -
CGT9486
Cogent Biosciences
Gastrointestinal Stromal Tumors
1 trial -
CGT9486, CGT9486
Cogent Biosciences
Advanced Systemic Mastocytosis
1 trial -
bezuclastinib
Cogent Biosciences
Advanced Systemic Mastocytosis (AdvSM)
1 trial -
ACTR T Cell Product
Cogent Biosciences
Solid Tumor
1 trial -
ACTR087
Cogent Biosciences
Multiple Myeloma
1 trial -
ACTR087
Cogent Biosciences
Lymphoma
1 trial -
ACTR707
Cogent Biosciences
Lymphoma
1 trial -
CGT4255
Cogent Biosciences
Advanced Solid Tumor, Adult
1 trial -
CGT6297
Cogent Biosciences
PIK3CA Mutations
1 trial
Frequently asked questions
How many clinical projects does Cogent Biosciences have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.